Edaravone dexborneol before thrombectomy improved 90-day independence only in LVO stroke patients with clinical-radiological mismatch in TASTE-2.
|Articles|March 6, 2005
- March 2005
- Volume 22
- Issue 3
Stent graft delivery system
Advertisement
Medtronic, Inc., has received Food and Drug Administration approval for its Xcelerant Delivery System for use with the AneuRx® AAA Stent Graft System for the treatment of abdominal aortic aneurysms. The Xcelerant is designed for greater control and improved deliverability. Kink-resistant catheter material improves trackability through tortuous arteries, and its integrated handle aids in precise placement of the stent. A distal radiopaque marker provides improved visibility during angiography for more accurate deployment.
Articles in this issue
over 21 years ago
Electronic medical records programover 21 years ago
Cardiac resynchronization therapy deviceover 21 years ago
Yes, we can prevent coronary heart disease in womenover 21 years ago
HDL better predictor of ischemic stroke than LDL, triglyceridesAdvertisement
Related to this article
Alia Galadari, MD, discusses subtle erythema, commonly missed diagnoses, and research gaps to help clinicians recalibrate their approach to skin of color.
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Kidney Compass: Final 2-Year TELIGAN Data for Telitacicept in IgA Nephropathy
5